Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year.

Labcorp beats Q2 profit and revenue estimates on demand for health tests

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 million Share repurchase authorization increased by $1.0 billion to $1.4 billion Launched important new tests in specialty testing areas Introduced Labcorp Global Trial Connect, a suite of central laboratory solutions aimed to accelerate clinical trials BURLINGTON, N.C. , Aug. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2024 and updated full-year guidance.

Labcorp Announces 2024 Second Quarter Results

Bio-Rad Laboratories

Bruker

Teleflex

Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.

What's in Store for These 4 MedTech Stocks in Q2 Earnings?

Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Labcorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amgen

Gilead Sciences

International Paper

Iron Mountain

Merck

Super Micro Computer

No one knows when the next S&P 500 crash will hit. But everyone should know which stocks to watch out for.

Look Out Below If You Still Own 7 Stocks When The Crash Comes

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Labcorp (LH) is a Strong Value Stock

Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

BURLINGTON, N.C. , July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024.

Labcorp to Announce Second Quarter Financial Results on August 1, 2024

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.

Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C. , June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced new strategic service offerings within its precision oncology portfolio.

Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C. , May 30, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 31 – June 4, 2024).

Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting

BURLINGTON, N.C., May 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the 44th Annual William Blair Growth Stock Conference on Tuesday, June 4 at 2:00 p.m.

Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference

Why Labcorp (LH) is a Top Value Stock for the Long-Term

Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.

Labcorp (LH) to Assess Preeclampsia Risk With New Test

Labcorp is now the only lab that can detect preeclampsia risk across all pregnancy trimesters BURLINGTON, N.C. , May 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of its first trimester preeclampsia screening test to be performed between 11 and 14 weeks gestation to determine the risk of developing preeclampsia before 34 weeks of pregnancy.

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy

Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m.

Labcorp to Webcast Its Annual Meeting of Shareholders

Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company,  announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.

Invitae Receives Court Approval for Sale to Labcorp

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.

FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Quest Diagnostics

WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorously opposed by the testing industry.

FDA brings lab tests under federal oversight in bid to improve accuracy and safety

Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for Labcorp Holdings Inc Stock (LH)